歌礼制药-B:2025中期报告

香港交易所
Sep 29

牛牛AI助手已提取核心信息歌礼制药公布2025年中期业绩,期内亏损同比收窄32.5%至人民币8,795万元,收入总额增长111.4%至1.04亿元。研发成本增加10.9%至1.47亿元,主要投向代谢性疾病产品管线。公司现金及等价物约18.28亿元,预计可支持至2029年的研发活动及运营。在代谢性疾病管线方面,ASC30每日一次口服片治疗肥胖症的美国Ib期研究显示,经28天治疗后体重下降高达6.5%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10